Summary
1 The effect of pre-dosing with 15 mg domperidone, a relatively selective dopamine 2-receptor antagonist, on the ocular hypotensive action of a single oral dose of 25 μg pergolide, a dopamine 2-receptor agonist, was studied in 9 normal human volunteers, using a non-invasive method.
2 Compared with domperidone followed after 1 h by placebo, placebo followed after 1 h by pergolide had an ocular hypotensive effect in both eyes. Domperidone followed after 1 h by pergolide had no effect on intraocular pressure in both eyes.
2 The results of this study showed that domperidone inhibited the ocular hypotensive action of pergolide, suggesting that pergolide reduces introcular pressure by the stimulation of the peripheral dopamine 2-receptors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Al-Sereiti MR and Turner P (1989) The effects of lisuride, terguride and bromocriptine on intraocular pressure (IOP). Br J Clin Pharmacol 27: 159–163
Al-Sereiti MR, Coakes RL, O'Sullivan PD and Turner P (1989 a) A comparison of the ocular hypotensive effect of 0.025% bromocriptine and 0.25% timolol eye drops in normal human volunteers. Br J Clin Pharmacol 28: 443–447
Al-Sereiti MR, Quik RFP and Turner P (1989 b) The effect of a single oral dose of pergolide on intraocular pressure and pupil diameter. Br J Clin Pharmacol 28: 263–268
Cavero I, Massingham R and Lefevre-Borg F (1982) Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Life Sci 31: 939–948
Fuller RW, Clemens JA, Kornfeld EC, Snoddy HD, Smalstig EB and Bach NJ (1979) Effects of (8B)-8-[(methylthio)methyl]-6-propylergoline on dopaminergic function and brain dopamine turnover in rats. Life Sci 24: 375–382
Geyer O, Robinson D, Lazar M, Lessing JB and Beyer R (1987) Hypotensive effect of bromocriptine in normal eyes. J Ocular Pharmacol 3: 1–4
Goldstein M, Liberman A, Lew JY, Asano T, Rosenfeld MR and Makman MH (1980) The interaction of pergolide with central dopaminergic receptors. Proc Natl Acad Sci USA 77: 3725–3728
Grolman B (1972) A new tonometer system. Am J Optometry Physiol Opt 49: 646–650
Kohli JD, Glock D and Goldberg LI (1983) Selective DA2 versus DA1 antagonist activity of domperidone in the periphery. Eur J Pharmacol 89: 137–141
Koller WC, Weinger WJ, Diamond BI, Nausieda PA and Klawans HL (1980) The pharmacological evaluation of pergolide mesylate as a potential antiParkinson agent. Neuropharmacol 19: 831–837
Laduron PM and Leysen JE (1979) Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol 28: 2161–2165
Mekki QA, Hassan SM and Turner P (1983) Bromocriptine lowers intraocular pressure without affecting blood pressure. Lancet I: 1250–1251
Mekki QA and Turner P (1985) Stimulation of dopamine receptors (type 2) lowers human intraocular pressure. Br J Ophthalmol 69: 909–910
Mekki QA, Warrington SJ and Turner P (1984) Bromocriptine eye drops lower intraocular pressure without affecting prolactin levels. Lancet I: 287–288
Potter DE, Burke JA and Chang FW (1984) Ocular hypotensive action of ergoline derivatives in rabbits: effects of sympathectomy and domperidone pretreatment. Curr Eye Res 3: 307–314
Turner P and Mekki QA (1985) Dopamine and intraocular pressure. Trends Pharmacol Sci 73: 348–349
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Al-Sereiti, M.R., Quik, R.F.P., Hedges, A. et al. Antagonism by domperidone of the ocular hypotensive effect of pergolide. Eur J Clin Pharmacol 38, 461–463 (1990). https://doi.org/10.1007/BF02336684
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02336684